Adverse events290

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

81 to 100 of 290

Type	Event	Organ system	Group	Affected	At risk
other	Upper respiratory tract infection	Infections and infestations	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	4	30
other	Upper respiratory tract infection	Infections and infestations	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	1	30
other	Upper respiratory tract infection	Infections and infestations	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	5	30
other	Upper respiratory tract infection	Infections and infestations	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	36	1,162
other	Upper respiratory tract infection	Infections and infestations	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	35	1,161
other	Viral infection	Infections and infestations	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	2	30
other	Viral infection	Infections and infestations	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	1	30
other	Viral infection	Infections and infestations	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	0	30
other	Viral infection	Infections and infestations	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	21	1,162
other	Viral infection	Infections and infestations	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	26	1,161
other	Alanine aminotransferase increased	Investigations	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	3	30
other	Alanine aminotransferase increased	Investigations	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	1	30
other	Alanine aminotransferase increased	Investigations	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	3	30
other	Alanine aminotransferase increased	Investigations	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	87	1,162
other	Alanine aminotransferase increased	Investigations	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	92	1,161
other	Arthralgia	Musculoskeletal and connective tissue disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	4	30
other	Arthralgia	Musculoskeletal and connective tissue disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	7	30
other	Arthralgia	Musculoskeletal and connective tissue disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	2	30
other	Arthralgia	Musculoskeletal and connective tissue disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	189	1,162
other	Arthralgia	Musculoskeletal and connective tissue disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	167	1,161

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03110770/events?page=5

API reference For AI assistants